EpiCast Report: Healthcare-Associated Gram-Negative Infections - Epidemiology Forecast to 2026

EpiCast Report: Healthcare-Associated Gram-Negative Infections - Epidemiology Forecast to 2026

Summary

Healthcare-associated infections (HAIs) are a major threat to patient safety. HAIs occur in hospitalized patients, and are not present at the time of admission. The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infections caused by Gram-negative bacteria are of particular public health concern, since they are at the root of approximately 30-70% of HAIs across the globe.

GlobalData epidemiologists forecast that the suspected incident cases of CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an Annual Growth Rate (AGR) of 0.60% per year over the next 10 years, from 2,592,739 cases in 2016 to 2,747,836 in 2026. In the 7MM, the US will have the highest number of suspected incident cases, with 1,311,068 in 2016, while Japan will have the lowest number of suspected incident cases, with 84,847 in 2016.

GlobalData epidemiologists forecast that the diagnosed incident cases of Gram-negative CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an AGR of 0.55% per year over the next 10 years, from 1,116,853 cases in 2016 to 1,178,754 cases in 2026. In the 7MM, the US will have the highest number of diagnosed incident cases, with 505,544 in 2016, while Japan will have the lowest number of diagnosed incident cases, with 41,245 in 2016.

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from national nosocomial surveillance systems and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the suspected incident cases of HAIs and diagnosed incident cases of Gram-negative HAIs. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for suspected and diagnosed incident cases of Gram-negative HAIs.

Scope

- The Healthcare-Associated Gram-Negative Infections EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of healthcare-associated Gram-negative infections in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of healthcare-associated infections (HAIs) and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites: catheter-associated urinary tract infection (CAUTI), central line-associated blood stream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infection site-specific diagnosed incident cases of Gram-negative HAIs are further segmented by causative agent (Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa).
- The Healthcare-Associated Gram-Negative Infections epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Healthcare-Associated Gram-Negative Infections EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global Gram-negative HAI market.
- Quantify patient populations in the global Gram-negative HAI market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gram-negative HAI therapeutics in each of the markets covered.
- Identify the percentage of suspected and diagnosed incident cases of Gram-negative HAIs by various clinical segmentations.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Healthcare-Associated Gram-Negative Infections: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 7
3.3 Global and Historical Trends 8
3.3.1 US 9
3.3.2 5EU 9
3.3.3 Japan 10
3.4 Forecast Methodology 10
3.4.1 Sources 11
3.4.2 Forecast Assumptions and Methods 15
3.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016-2026) 23
3.5.1 Suspected Incident Cases of Select HAIs 23
3.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs 24
3.5.3 Suspected Incident Cases of Select HAIs by Infection Site 25
3.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site 26
3.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent 27
3.6 Discussion 31
3.6.1 Epidemiological Forecast Insight 31
3.6.2 Limitations of the Analysis 32
3.6.3 Strengths of the Analysis 33
4 Appendix 34
4.1 Bibliography 34
4.2 Primary Research - Key Opinion Leaders Interviewed for this Report 38
4.3 Primary Research - Prescriber Survey 41
4.4 About the Authors 42
4.4.1 Epidemiologist 42
4.4.2 Reviewers 42
4.4.3 Global Director of Therapy Analysis and Epidemiology 43
4.4.4 Global Head and EVP of Healthcare Operations and Strategy 43
4.5 About GlobalData 44
4.6 Contact Us 44
4.7 Disclaimer 44

List Of Tables

Table 1: Risk Factors for Diagnosed Incident Cases of HAIs 8
Table 2: 7MM, Suspected Incident Cases of Select HAIs, Ages 18 Years, Both Sexes, N, Select Years 2016-2026 24
Table 3: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages 18 Years, Both Sexes, N, Select Years 2016-2026 25
Table 4: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country and Specialty 41

List Of Figures

Figure 1: 7MM, Suspected Incident Cases of Select HAIs, Both Sexes, Ages 18 Years, 2016 and 2026 5
Figure 2: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Both Sexes, Ages 18 Years, 2016 and 2026 6
Figure 3: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site 13
Figure 4: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site 14
Figure 5: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent 15
Figure 6: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016 26
Figure 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016 27
Figure 8: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages 18 Years, 2016 28
Figure 9: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages 18 Years, 2016 29
Figure 10: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages 18 Years, 2016 30
Figure 11: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages 18 Years, 2016 31

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available